A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2017
At a glance
- Drugs PDR 001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2017 Planned End Date changed from 1 Jul 2017 to 18 Sep 2017.
- 30 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 18 Sep 2017.
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.